# Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients

> **NCT01554852** · PHASE3 · UNKNOWN · sponsor: **University of Leeds** · enrollment: 4420 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen
- **DRUG:** Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen
- **DRUG:** Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen
- **DRUG:** Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen
- **DRUG:** Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen
- **DRUG:** Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen
- **DRUG:** Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance
- **DRUG:** Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance
- **DRUG:** High dose melphalan therapy and autologous stem cell transplant (intensive pathway only)

## Key facts

- **NCT ID:** NCT01554852
- **Lead sponsor:** University of Leeds
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-05
- **Primary completion:** 2021-12
- **Final completion:** 2022-12
- **Target enrollment:** 4420 (ACTUAL)
- **Last updated:** 2018-06-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01554852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01554852, "Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01554852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*